Anula Jayasuriya - Dec 29, 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: Director
Signature: /s/ Alexandra Hernandez, as Attorney-in Fact
Stock symbol: LCTX
Transactions as of: Dec 29, 2023
Transactions value $: $10,900
Form type: 4
Date filed: 1/2/2024, 07:08 PM
Previous filing: Jul 3, 2023
Next filing: Jul 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares, no par value	Purchase	$10.9K	+10K		$1.09	10K	Dec 29, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.08 to not more than $1.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
F2	Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.

Content

The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.08 to not more than $1.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.

Does not include common shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.